Aktis Oncology (AKTS) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LB Pharmaceuticals is the larger company by market cap ($1.12 billion vs $986.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | LBRX |
|---|---|---|
| Share price | $17.74 | $34.61 |
| Market cap | $986.69M | $1.12B |
| 1-day change | -1.44% | +1.32% |
| YTD return | — | +55.48% |
| 1-year return | — | +130.12% |
| P/E ratio (TTM) | — | 346.10 |
| EPS (TTM) | $-1.70 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $50.16 |
| 52-week low | $14.72 | $14.32 |
| Distance from 52-week high | -48.11% | -31.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.49% | +65.56% |
| Average volume | 366.06K | 341.17K |
| Shares outstanding | 53.75M | 32.26M |
| Employees | 79 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
AKTS vs LBRX FAQ
Which is bigger, Aktis Oncology or LB Pharmaceuticals?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.12B compared with $986.69M for Aktis Oncology (AKTS).
Are Aktis Oncology and LB Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.